Key Points
- On Dec. 2, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics at an average price of $63.89 for $140,558, leaving him with 140,610 shares — a 1.54% drop in his ownership (≈$8.98M value).
- Malik has made multiple similar sales since September (several transactions of ~2,000+ shares each), signaling a pattern of ongoing insider selling.
- Analysts hold a Moderate Buy consensus with an average price target of $79.29; the company recently beat EPS expectations (‑$1.54 vs. ‑$1.59) but missed revenue estimates ($1.94M vs. $6.05M), and the stock sits near its 52‑week high ($69.33).
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $63.89, for a total transaction of $140,558.00. Following the sale, the executive vice president owned 140,610 shares in the company, valued at approximately $8,983,572.90. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, November 18th, Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock. The stock was sold at an average price of $66.45, for a total transaction of $146,190.00.
- On Tuesday, November 4th, Fady Ibraham Malik sold 2,295 shares of Cytokinetics stock. The stock was sold at an average price of $59.55, for a total transaction of $136,667.25.
- On Tuesday, October 21st, Fady Ibraham Malik sold 2,105 shares of Cytokinetics stock. The shares were sold at an average price of $58.22, for a total value of $122,553.10.
- On Tuesday, October 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $60.56, for a total value of $121,120.00.
- On Tuesday, September 23rd, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $49.28, for a total value of $98,560.00.
- On Tuesday, September 9th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $51.29, for a total value of $102,580.00.
Cytokinetics Price Performance
Cytokinetics stock opened at $63.51 on Wednesday. The firm has a market capitalization of $7.76 billion, a P/E ratio of -10.10 and a beta of 0.58. The stock has a fifty day moving average price of $60.92 and a two-hundred day moving average price of $45.75. Cytokinetics, Incorporated has a 52-week low of $29.31 and a 52-week high of $69.33.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, beating the consensus estimate of ($1.59) by $0.05. The firm had revenue of $1.94 million during the quarter, compared to analyst estimates of $6.05 million. During the same quarter in the prior year, the firm posted ($1.36) EPS. The firm's revenue for the quarter was up 318.1% on a year-over-year basis. On average, equities research analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on CYTK. Bank of America raised their price objective on shares of Cytokinetics from $52.00 to $56.00 and gave the stock a "neutral" rating in a report on Thursday, October 2nd. UBS Group restated a "neutral" rating and set a $61.00 price target on shares of Cytokinetics in a research report on Monday. Royal Bank Of Canada raised their price target on Cytokinetics from $82.00 to $87.00 and gave the company an "outperform" rating in a report on Tuesday, November 11th. Stifel Nicolaus boosted their price objective on Cytokinetics from $87.00 to $96.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen cut Cytokinetics from a "hold" rating to a "sell" rating in a report on Saturday, November 8th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $79.29.
Get Our Latest Stock Report on Cytokinetics
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Woodline Partners LP boosted its position in Cytokinetics by 676.1% in the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company's stock valued at $90,559,000 after buying an additional 1,435,422 shares during the last quarter. Norges Bank acquired a new position in shares of Cytokinetics during the second quarter valued at $39,122,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lifted its stake in shares of Cytokinetics by 571.2% during the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 1,082,563 shares of the biopharmaceutical company's stock valued at $35,768,000 after acquiring an additional 921,278 shares during the period. Paradigm Biocapital Advisors LP bought a new position in Cytokinetics in the first quarter valued at about $34,510,000. Finally, Deep Track Capital LP increased its position in Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company's stock worth $236,328,000 after purchasing an additional 650,000 shares during the period.
About Cytokinetics
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
